Dutch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

prolactinoma/triglyceride

De link wordt op het klembord opgeslagen
LidwoordKlinische proevenOctrooien
Bladzijde 1 van 19 resultaten

[Serum concentrations of glucose, cholesterol and triglycerides in men with prolactinoma treated with cabergoline].

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in

Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
OBJECTIVE Increasing evidence exists that hyperprolactinemia alters metabolic profile. The mechanism of this effect is unknown. We aimed to investigate the differences between the metabolic profile of patients with prolactinomas and nonfunctional pituitary adenomas and to evaluate the impact of

Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
Previous studies suggest that hyperprolactinaemia might have adverse effects on lipid and glucose metabolism. We therefore aimed to evaluate whether dopamine agonist treatment with cabergoline has significant effects on blood lipids, fasting glucose and HbA1c levels in patients with micro- or
Deranged metabolic profiles and insulin resistance (IR) have been documented in patients with prolactinomas. Few data are yet available on the apolipoprotein (apo) B/apoA-I ratio and its relationship with IR in patients with prolactinomas. This study was aimed to evaluate the level of apoB/apoA-I

Hyperprolactinemia has no effect on plasma ghrelin levels in patients with prolactinoma.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
OBJECTIVE Accumulating evidence suggests that prolactin is a modulator of body weight and composition and that it regulates some transporters in adipose tissue. It was demonstrated that hyperprolactinemia is associated with weight gain and obesity. Ghrelin is a novel hormone secreted from many

Preclinical atherosclerosis in patients with prolactinoma.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
OBJECTIVE The aim of this study was to evaluate the effect of hyperprolactinemia on body fat, insulin sensitivity, inflammatory markers, and cardiovascular risk in patients with prolactinoma. METHODS The study included 35 untreated hyperprolactinemic patients with pituitary adenomas, and 36 age-,

Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
Serum total cholesterol and triglyceride levels were determined in forty-seven women with prolactinoma and in eighty-four age- and weight-matched control women. Oral glucose tolerance tests (OGTT) were performed and postheparin plasma lipoprotein lipase (LPL) and hepatic lipase (HL) activities were
Although bromocriptine is the mainstay of treatment of macroprolactinomas, its therapeutic usefulness may be limited by poor tolerance, lack of consistent reduction in serum prolactin levels and tumour size, and the necessity for multiple dosing. Consequently new dopamine agonists have been

Prolactinoma: a condition associated with hypoadiponectinemia.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
Prolactinomas are prolactin-secreting neoplasias accounting for 40% of the pituitary adenomas. Much is known about the effects of prolactinomas on the reproductive system, but few data are yet available regarding their induced changes on metabolism. This study was aimed at evaluating patients with
OBJECTIVE Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly diagnosed prolactinoma in relation to disease
Hyperprolactinemia is associated with endothelial dysfunction and atherogenic risk factors, but carotid intima media thickness (IMT) has not been studied in hyperprolactinemic patients. To determine whether untreated hyperprolactinemia contributes to increased carotid IMT. Thirty-one prolactinoma

Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
Recent large cohort studies suggest an association between high plasma prolactin and cardiovascular mortality. The objective of this systematic review was to systematically assess the effect of reducing prolactin with dopamine agonist on established cardiovascular risk factors in

BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
Hyperprolactinemia might be related to weight gain, metabolic syndrome (MS), and insulin resistance (IR). Treatment with dopamine agonist (DA) has been shown to reduce body weight and improve metabolic parameters. The objectives of this study were to determine the prevalence of obesity, overweight,

Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND Hyperprolactinemia has been associated with changes in body composition and metabolic abnormalities. Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. This study was designed to assess the anthropometric and metabolic alterations

Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
Prolactin is a metabolic hormone. The hypothesis is that hyperprolactinemia can cause metabolic and inflammatory changes which are associated with accelerated atherosclerotic process, but the treatment of hyperprolactinemia with dopamine agonists, leads to reversibility of these processes. The first
Word lid van onze
facebookpagina

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap

  • Werkt in 55 talen
  • Kruidengeneesmiddelen gesteund door de wetenschap
  • Kruidenherkenning door beeld
  • Interactieve GPS-kaart - tag kruiden op locatie (binnenkort beschikbaar)
  • Lees wetenschappelijke publicaties met betrekking tot uw zoekopdracht
  • Zoek medicinale kruiden op hun effecten
  • Organiseer uw interesses en blijf op de hoogte van nieuwsonderzoek, klinische onderzoeken en patenten

Typ een symptoom of een ziekte en lees over kruiden die kunnen helpen, typ een kruid en zie ziekten en symptomen waartegen het wordt gebruikt.
* Alle informatie is gebaseerd op gepubliceerd wetenschappelijk onderzoek

Google Play badgeApp Store badge